Preclinical Safety Evaluation of Intravitreal Injection of Full-Length Humanized Vascular Endothelial Growth Factor Antibody in Rabbit Eyes

PURPOSE. To evaluate the preclinical safety of intravitreal bev-acizumab, which is a full-length humanized monoclonal anti-body against the vascular endothelial growth factor (VEGF), in rabbit eyes over a short-term period. METHODS. Twenty-four rabbits were divided into two groups, each with two subgroups. The first group (groups 1 and 2) received 1.25 mg (0.05 mL) intravitreal bevacizumab, and the second group (groups 3 and 4) received 3.00 mg (0.12 mL) intravitreal bevacizumab. The right eyes were designated as the study eyes, and the left eyes served as a control and received the same volume of saline intravitreally. Groups 1 and 3 were labeled as early groups and scheduled to be terminated at 14 days. Groups 2 and 4, labeled as late groups, were scheduled to be terminated at 28 days. Besides electroretinography (ERG) and visually evoked potentials (VEP), central corneal thickness